Yomiuri: Fujirebio Submits Blood Test Kit for Early Alzheimer's Detection for Approval to Japan Health Ministry

Dow Jones

11/26

By Nozomi Suzuki / Yomiuri Shimbun Staff Writer

Japanese testing reagent maker Fujirebio Inc. announced on Tuesday that it has applied to the Japanese Health, Labor and Welfare Ministry for approval to manufacture and sell a blood test kit to assist in diagnosing Alzheimer's disease. The kit is expected to reduce the burden on patients compared to conventional tests, and lead to earlier diagnosis.

Alzheimer's disease is thought to occur when abnormal proteins called "amyloid beta" and "tau" accumulate in the brain, damaging nerve cells and leading to cognitive decline. The test kit measures the concentration of these proteins in plasma, according to the company.

Currently, the procedures for diagnosis include expensive imaging tests like "amyloid PET" scans and invasive lumbar puncture procedures to test cerebrospinal fluid. If approved, Fujirebio's test would only require a blood draw, thus reducing the burden on patients and believed to make testing more accessible.

----

This article is from The Yomiuri Shimbun. Neither Dow Jones Newswires, MarketWatch, Barron's nor The Wall Street Journal were involved in the creation of this content.

YDN-M0000160789-1

(END) Dow Jones Newswires

November 26, 2025 02:36 ET (07:36 GMT)

Copyright (c) 2025 The Yomiuri Shimbun

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2586239944"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2586239944\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2586239944?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-26 15:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2586239944","market":"nz","top_or_hot":-1,"title":"Yomiuri: Fujirebio Submits Blood Test Kit for Early Alzheimer's Detection for Approval to Japan Health Ministry","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Nozomi Suzuki / Yomiuri Shimbun Staff Writer \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Japanese testing reagent maker Fujirebio Inc. announced on Tuesday that it has applied to the Japanese Health, Labor and Welfare Ministry for approval to manufacture and sell a blood test kit to assist in diagnosing Alzheimer's disease. The kit is expected to reduce the burden on patients compared to conventional tests, and lead to earlier diagnosis. \n</p>\n<p>\n  Alzheimer's disease is thought to occur when abnormal proteins called \"amyloid beta\" and \"tau\" accumulate in the brain, damaging nerve cells and leading to cognitive decline. The test kit measures the concentration of these proteins in plasma, according to the company. \n</p>\n<p>\n  Currently, the procedures for diagnosis include expensive imaging tests like \"amyloid PET\" scans and invasive lumbar puncture procedures to test cerebrospinal fluid. If approved, Fujirebio's test would only require a blood draw, thus reducing the burden on patients and believed to make testing more accessible. \n</p>\n<p>\n    ---- \n</p>\n<p>\n  This article is from The Yomiuri Shimbun. Neither Dow Jones Newswires, MarketWatch, Barron's nor The Wall Street Journal were involved in the creation of this content. \n</p>\n<p>\n  YDN-M0000160789-1 \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 26, 2025 02:36 ET (07:36 GMT)\n</p>\n<p>\n  Copyright (c) 2025 The Yomiuri Shimbun\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Yomiuri: Fujirebio Submits Blood Test Kit for Early Alzheimer's Detection for Approval to Japan Health Ministry</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nYomiuri: Fujirebio Submits Blood Test Kit for Early Alzheimer's Detection for Approval to Japan Health Ministry\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-11-26 15:36</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Nozomi Suzuki / Yomiuri Shimbun Staff Writer \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Japanese testing reagent maker Fujirebio Inc. announced on Tuesday that it has applied to the Japanese Health, Labor and Welfare Ministry for approval to manufacture and sell a blood test kit to assist in diagnosing Alzheimer's disease. The kit is expected to reduce the burden on patients compared to conventional tests, and lead to earlier diagnosis. \n</p>\n<p>\n  Alzheimer's disease is thought to occur when abnormal proteins called \"amyloid beta\" and \"tau\" accumulate in the brain, damaging nerve cells and leading to cognitive decline. The test kit measures the concentration of these proteins in plasma, according to the company. \n</p>\n<p>\n  Currently, the procedures for diagnosis include expensive imaging tests like \"amyloid PET\" scans and invasive lumbar puncture procedures to test cerebrospinal fluid. If approved, Fujirebio's test would only require a blood draw, thus reducing the burden on patients and believed to make testing more accessible. \n</p>\n<p>\n    ---- \n</p>\n<p>\n  This article is from The Yomiuri Shimbun. Neither Dow Jones Newswires, MarketWatch, Barron's nor The Wall Street Journal were involved in the creation of this content. \n</p>\n<p>\n  YDN-M0000160789-1 \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 26, 2025 02:36 ET (07:36 GMT)\n</p>\n<p>\n  Copyright (c) 2025 The Yomiuri Shimbun\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK6031","symbol_name":"特种化学制品","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2586239944","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2586239944","pubTimestamp":1764142560,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Japanese testing reagent maker Fujirebio Inc. announced on Tuesday that it has applied to the Japanese Health, Labor and Welfare Ministry for approval to manufacture and sell a blood test kit to assist in diagnosing Alzheimer's disease. The kit is expected to reduce the burden on patients compared to conventional tests, and lead to earlier diagnosis.Alzheimer's disease is thought to occur when abnormal proteins called \"amyloid beta\" and \"tau\" accumulate in the brain, damaging nerve cells and leading to cognitive decline. The test kit measures the concentration of these proteins in plasma, according to the company.Currently, the procedures for diagnosis include expensive imaging tests like \"amyloid PET\" scans and invasive lumbar puncture procedures to test cerebrospinal fluid. If approved, Fujirebio's test would only require a blood draw, thus reducing the burden on patients and believed to make testing more accessible.This article is from The Yomiuri Shimbun. Neither Dow Jones Newswire","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK6031":"特种化学制品","SG9999001069.SGD":"UOB UNITED ASIA PACIFIC GROWTH (SGD) ACC","BK6102":"燃气公用事业","SG9999003461.SGD":"United Asia Pacific Infrastructure SGD","A7RU.SI":"吉宝基础设施信托","BK6501":"化工股","SG9999004360.SGD":"Nikko AM Shenton Thrift Fund SGD","SG9999002950.SGD":"United Asian Growth Opportunities SGD","SG9999003826.SGD":"日兴资管新加坡股息基金 SGD"},"translate_title":"读卖新闻：Fujirebio向日本厚生省提交用于早期阿尔茨海默病检测的血液检测试剂盒以供批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"A7RU.SI":1.5},"content_text":"By Nozomi Suzuki / Yomiuri Shimbun Staff Writer \n\n\n \n\n\n  Japanese testing reagent maker Fujirebio Inc. announced on Tuesday that it has applied to the Japanese Health, Labor and Welfare Ministry for approval to manufacture and sell a blood test kit to assist in diagnosing Alzheimer's disease. The kit is expected to reduce the burden on patients compared to conventional tests, and lead to earlier diagnosis. \n\n\n  Alzheimer's disease is thought to occur when abnormal proteins called \"amyloid beta\" and \"tau\" accumulate in the brain, damaging nerve cells and leading to cognitive decline. The test kit measures the concentration of these proteins in plasma, according to the company. \n\n\n  Currently, the procedures for diagnosis include expensive imaging tests like \"amyloid PET\" scans and invasive lumbar puncture procedures to test cerebrospinal fluid. If approved, Fujirebio's test would only require a blood draw, thus reducing the burden on patients and believed to make testing more accessible. \n\n\n    ---- \n\n\n  This article is from The Yomiuri Shimbun. Neither Dow Jones Newswires, MarketWatch, Barron's nor The Wall Street Journal were involved in the creation of this content. \n\n\n  YDN-M0000160789-1 \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 26, 2025 02:36 ET (07:36 GMT)\n\n\n  Copyright (c) 2025 The Yomiuri Shimbun","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}